| Budget Amount *help |
¥25,610,000 (Direct Cost: ¥19,700,000、Indirect Cost: ¥5,910,000)
Fiscal Year 2020: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2019: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2018: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2017: ¥11,960,000 (Direct Cost: ¥9,200,000、Indirect Cost: ¥2,760,000)
|
|---|
| Outline of Final Research Achievements |
Through this project, the methods of generating human induced pluripotent stem (iPS) cell-derived alveolar epithelial cells and their long-term culture have been established. The differentiation process from the lung progenitor cells to alveolar epithelial cells was delineated at the single-cell level. Not only human iPS cell-derived alveolar type II (iAT2) cells but also alveolar type I (iAT1) cells were identified. Each transcriptome was compared and thereby the method of directing differentiation from iAT2 to iAT1 cells was established. On the other hand, iAT2 cells can possess and secrete lamellar bodies, organelles to restore pulmonary surfactant. Gene editing technology has made it possible to establish disease modeling of rare hereditary diseases in a dish. And a method of safe transfer of alveolar organoids intratracheally to mouse was developed and the iPSC-derived cells were successfully engrafted on the living mouse lung without generating tumor-like lesion.
|
